Sanofi Group

Sanofi is a top-10 global pharma company leading in vaccines, rare diseases, and consumer healthcare, generating €43B+ annually with key products like Dupixent.

概述

Sanofi — France's largest pharmaceutical company and a top-10 global pharma player generating €43B+ annually, with leadership in vaccines, rare diseases, and consumer healthcare.

历史时间线

• 1973: Sanofi founded by Elf Aquitaine (French oil company) as pharmaceutical division
• 1999: Merger with Synthélabo creates Sanofi-Synthélabo
• 2004: Acquires Aventis for €52B; becomes Sanofi-Aventis
• 2011: Acquires Genzyme for $20B; enters rare disease market
• 2019: Acquires Bioverativ; renames to Sanofi
• 2020: COVID-19 vaccine development partnership with GSK (later pivots to mRNA)
• 2023: Paul Hudson becomes CEO; announces 'Play to Win' strategy
• 2024: €43B+ revenue; immunology and rare diseases driving growth

商业模式

Three operating segments: Pharmaceuticals (specialty care, immunology, rare diseases, ~60% of revenue), Vaccines (influenza, pediatric, travel, ~20%), and Consumer Healthcare (OTC medicines, vitamins, ~20%). Key products include Dupixent (immunology, $10B+ blockbuster), Dupilumab pipeline, and vaccine portfolio including flu and polio.

护城河分析

Vaccine manufacturing scale: Sanofi is the world's largest vaccine producer by volume, with facilities on 5 continents. Dupixent moat: the immunology drug generates $10B+ annually with 10+ years of patent protection remaining. Rare disease expertise: Genzyme acquisition gave Sanofi deep capabilities in enzyme replacement therapies. European regulatory relationships provide faster EU approvals.

关键数据

• revenue: €43+ billion (2023)
• employees: 90,000+ in 100+ countries
• key_product: Dupixent ($10B+ blockbuster with Regeneron partnership)
• r_and_d: ~€6 billion annually
• headquarters: Paris, France

有趣事实

• Sanofi's vaccine division produces over 2 billion doses annually — that's roughly one vaccine for every four people on Earth each year
• The Genzyme acquisition in 2011 was controversial at the time ($20.1B for a company with one key product), but it gave Sanofi the rare disease expertise that now generates €8B+ annually